ENDO Annual Meeting 2026

XLH Adults: Osteomalacia Persists Despite Conventional Therapy

Adults with X-linked hypophosphatemia (XLH) frequently experience persistent osteomalacia, even with conventional phosphate and active vitamin D treatment.

Endocrinologists' Role in Early Thyroid Eye Disease Recognition

Early recognition of thyroid eye disease (TED) by endocrinologists is critical for optimal patient outcomes, enabling timely intervention.

Classic CAH: New Approaches to Glucocorticoid Dosing

Endocrinology specialists are re-evaluating glucocorticoid dosing strategies for classic congenital adrenal hyperplasia (CAH), focusing on individualised regimens to balance androgen control and minimise adverse effects.

Afirma Molecular Testing: Unique Situations and New Prognostic Development

Afirma molecular testing aids thyroid nodule management, particularly in indeterminate cytology. New prognostic markers enhance risk stratification.

Defining Hyperphagia Treatment Possibilities in Prader-Willi Syndrome

Clinician and caregiver perspectives highlight the complex challenges and unmet needs in managing hyperphagia in Prader-Willi Syndrome.

GLP-1 RAs Reduce CV Risk in T2D Via Weight, Glucose Pathways

GLP-1 receptor agonists offer cardiovascular risk reduction in type 2 diabetes through both weight loss and direct glucose-lowering mechanisms.

Liver-Directed Treatment Shows Efficacy in Metabolic Dysfunction

A novel liver-directed treatment presented at endo 2026 offers a targeted approach for metabolic dysfunction, addressing a significant unmet clinical need.

Desmopressin Dosing Refined for Central Diabetes Insipidus

New insights into desmopressin administration for central diabetes insipidus (CDI) aim to optimise efficacy and minimise hyponatremia risk.

Hypoparathyroidism Treatment: Patient, Care Partner, HCP Perspectives

New perspectives on hypoparathyroidism treatment from patients, care partners, and HCPs highlight unmet needs and treatment goals.

Severe Hypoglycemia in T1D: Enhancing Patient-Clinician Dialogue

Addressing severe hypoglycemic events in type 1 diabetes requires direct, empathetic clinician-patient conversations to improve management and outcomes.

Low Alkaline Phosphatase: Recognizing Clinical Consequences

Low alkaline phosphatase (ALP) is often overlooked, but its clinical consequences, particularly hypophosphatasia, warrant increased diagnostic vigilance.

Cushing's Syndrome: Addressing Diagnostic Delays and Treatment Gaps

Cushing's syndrome presents a diagnostic challenge, often leading to significant delays in treatment initiation and suboptimal patient outcomes.

Endo 2026: Risk-Based Osteoporosis Management Refines Clinical Practice

Endo 2026 highlighted refined risk-based strategies for osteoporosis care, advocating for tailored interventions beyond universal guidelines to improve patient outcomes.

Korlym® for Cushing's Syndrome: Patient Experience, Side Effects and 2026 Clinical Data

Patient-reported outcomes from Endo 2026 show Korlym® (mifepristone) cuts weight gain, fatigue and mood disturbances in Cushing's syndrome. Covers mechanism of cortisol receptor blockade, side effect profile, and how it compares to relacorilant.

12 Months of Romosozumab Builds Bone Density in Postmenopausal Osteoporosis

A 12-month course of romosozumab significantly increases bone mineral density in postmenopausal women with osteoporosis.

Hypothyroidism: Symptom Burden Persists Despite Euthyroidism

Many patients with hypothyroidism report persistent symptoms despite achieving biochemical euthyroidism, highlighting a significant symptom-treatment gap.

Hypercortisolism: Emerging Diagnostic and Management Insights

New evidence presented at Endo 2026 refines our understanding of hypercortisolism, impacting diagnostic strategies and therapeutic approaches.

Obesity Care: Tailored Treatment Strategies Highlighted at endo 2026

Personalised treatment approaches for obesity, moving beyond a 'one-size-fits-all' model, were a key focus at endo 2026.

Acromegaly Management: Focus on Biochemical Control at ENDO 2026

New insights from ENDO 2026 highlight the persistent challenges in achieving biochemical control for acromegaly patients.

Steroidogenesis Inhibitor Targets Root Cause of Cushing’s Syndrome

A novel steroidogenesis inhibitor presented at ENDO 2026 offers a targeted approach to endogenous Cushing's syndrome by reducing cortisol overproduction.

Peer Insights on Once-Daily Weight Management Therapy at endo 2026

Endocrinology specialists discussed the clinical utility of a once-daily treatment for weight management in appropriate adult patients.

Desiccated Thyroid Extract: Efficacy and Safety in Hypothyroidism

A case-based discussion at endo 2026 reviewed the role of desiccated thyroid extract (DTE) in hypothyroidism management, highlighting patient selection and comparative efficacy.